Expression of hypoxia inducible factor-1α in tumors of patients with glioblastoma multiforme and transitional meningioma

Journal of Clinical Neuroscience

Volumn 15, Issue 9, 2008, Pages 1036-1042

  Kaynar, Mehmet Yasar ^a   Sanus, Galip Zihni ^a   Hnimoglu, Hakan ^a   Kacira, Tibet ^a   Kemerdere, Rahsan ^a   Atukeren, Pinar ^a   Gumustas, Koray ^a   Canbaz, Bulent ^a   Tanriverdi, Taner ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Brain tumors; Glioblastoma multiforme; HIF 1; Hypoxia; Meningioma

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; ANOXIA; BRAIN NEOPLASMS; CELL HYPOXIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 48449105134     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2007.07.080     Document Type: Article

References (70)

1. Chan D.A., Sutphin P.D., Denko N.C., et al. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 277 (2002) 40112-40117
2. Chun Y.S., Choi E., Kim T.Y., et al. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxiainducible factor-1α gene. Biochem J 362 (2002) 71-79
3. Rapisarda A., Uranchimeg B., Scudiero D.A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor-1 transcriptional activation pathway. Cancer Res 62 (2002) 4316-4324
4. 2 tension. Proc Natl Acad Sci USA 92 (1995) 5510-5514
5. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270 (1995) 1230-1237
6. Chun Y.S., Choi E., Kim G.T., et al. Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1α. Eur J Biochem 267 (2000) 4198-4204
7. Narravula S., and Colgan S.P. Hypoxia-Inducible Factor-1-mediated inhibition of peroxisome proliferator-activated receptor α expression during hypoxia. J Immunol 166 (2001) 7543-7548
8. Shoshani T., Faerman A., Mett I., et al. Identification of a novel hypoxia-inducible factor-1 responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 22 (2002) 2283-2293
9. Zhong H., De Marco A., Laughner E., et al. Over-expression of hypoxia-inducible factor 1α in common human cancers and metastases. Cancer Res 59 (1999) 5830-5835
10. Brahimi-Horn M.C., and Pouyssegur J. Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol 73 (2007) 450-457
11. Claus E.B., Bondy M.L., Schildkraut J.M., et al. Epidemiology of intracranial meningioma. Neurosurgery 57 (2005) 1088-1095
12. Merighi S., Benini A., Mirandola P., et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 72 (2006) 19-31
13. Acker T., and Acker H. Cellular oxygen sensing need in CNS function: physiological and pathological implications. J Exper Biol 207 (2004) 3171-3188
14. Greijer A.E., and van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57 (2004) 1009-1014
15. Irie N., Matsuo T., and Nagata I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 21 (2004) 1-6
16. Lazaro-Lopez M. Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 15 (2006) 12-15
17. Powis G., and Kirkpatrick L. Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 3 (2004) 647-654
18. Schmid T., Zhou J., and Brüne B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 4 (2004) 423-431
19. Vaupe P. The role of hypoxia-induced factors in tumor progression. Oncologist 9 (2004) 10-17
20. Zagorska A., and Dulak J. HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Polon 51 (2004) 563-585
21. Korkolopoulou P., Patsouris E., Konstantinidou P.M., et al. Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Neurobiol 30 (2004) 267-278
22. Sondergaard K.L., Hilton D.A., Pernney M., et al. Expression of hypoxia-inducible factor 1α in tumors of patients with glioblastoma. Neuropathol Neurobiol 28 (2002) 210-217
23. Jensen R.L., Soleau S., Bhayani M.K., et al. Expression of hypoxia-inducible factor-1 alpha and correlation with preoperative embolization of meningiomas. J Neurosurg 97 (2002) 658-667
24. Daumas-Duport C., Scheithauer B., O'Fallon J., et al. Grading of astrocytomas. A simple and reproducible method. Cancer 62 (1988) 2152-2165
25. Senger D., Cairncross J.G., and Forsyth P.A. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?. Cancer J 9 (2003) 214-221
26. Black P.M. Meningiomas. Neurosurgery 32 (1993) 643-657
27. Claus E.B., Bondy M.L., Schildkraut J.M., et al. Epidemiology of intracranial meningioma. Neurosurgery 57 (2005) 1088-1095
28. Drummond K.J., Zhu J.J., and Black P.M. Meningiomas: Updating basic science, management, and outcome. Neurologist 10 (2004) 113-130
29. Rong Y., Durden D.L., van Meir E.G., et al. Pseudopalisading necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol 6 (2006) 529-539
30. Barker F.G., Davis R.L., Chang S.M., et al. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77 (1996) 1161-1166
31. Samoto K., Ikezaki K., Ono M., et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55 (1995) 1189-1193
32. Yamasaki F., Yoshioka H., Hama S., et al. Recurrence of meningiomas. Cancer 89 (2000) 1102-1110
33. Yoshioka H., Hama S., Taniguchi E., et al. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 85 (1999) 936-944
34. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12 (1998) 149-162
35. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor I. Mol Cell Biol 16 (1996) 4604-4613
36. Gleadle J.M., and Ratcliffe P.J. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 89 (1997) 503-509
37. Jiang B.H., Semenza G.L., Bauer C., et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271 (1996) C1172-C1180
38. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15 (1999) 551-578
39. Semenza G.L., Nejfelt M.K., Chi S.M., et al. Hypoxia-inducible nuclear factors bind to enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci 88 (1991) 5680-5684
40. Brat D.J., and Mapstone T.B. Malignant glioma physiology: Cellular response to hypoxia and its role in tumor progression. Ann Intern Med 138 (2003) 659-668
41. Compostella A., Tosoni A., Blatt V., et al. Prognostic factors for anaplastic astrocytomas. J Neurooncol 26 (2006) 1-9
42. Flamme I., Krieg M., and Plate K.H. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α. Am J Pathol 153 (1998) 25-29
43. Jensen R.L., Ragel B.T., Whang K., et al. Inhibition of hypoxia-inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neuro-Oncol 78 (2006) 233-247
44. Preusser M., Wolfsberger S., Haberler C., et al. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol 109 (2005) 211-216
45. Birner P., Gatterbauer B., Oberhuber G., et al. Expression of hypoxia-inducible factor-1 α in oligodendrogliomas. Its impact on prognosis and on neoangiogenesis. Cancer 92 (2001) 165-171
46. Talks K.L., Turley H., Gatter K.C., et al. The expression and distribution of the hypoxia-inducible factors HIF-1a and HIF-2a in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157 (2000) 411-421
47. Plate K.H., and Risau W. Angiogenesis in malignant gliomas. Glia 15 (1995) 339-347
48. Pietsch T., Valter M.M., Wolf H.K., et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93 (1997) 109-117
49. Smits A., and Funa K. Platelet-derived growth factor (PDGF) in primary brain tumors of neuroglial origin. Histol Histopathol 13 (1998) 511-520
50. Birner P., Schindl M., Obermair A., et al. Expression of hypoxia-inducible factor (HIF) 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
51. Zagzag D., Zhong H., Scalzetti J., et al. Expression of hypoxia-inducible factor-1a in brain tumors: association with angiogenesis, invasion and progression. Cancer 88 (2000) 2606-2618
52. Acker T., and Plate K.H. Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 117 (2004) 219-248
53. Fischer I., Gagner J.P., Law M., et al. Angiogenesis in gliomas: Biology and molecular pathophysiology. Brain Pathol 15 (2005) 297-310
54. Al-Khalaf H.H., Lach B., Allam A., et al. The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells. J Neurooncol 83 (2007) 9-15
55. Wang J.L., Zhang Z.J., Hartman M., et al. Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DANN sequencing techniques on paraffin-embedded samples. Int J Cancer 64 (1995) 223-228
56. Joachim T., Ram Z., Rappaport Z.H., et al. Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer 94 (2001) 218-221
57. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degredation of hypoxia-inducible factor 1α. Genes Dev 14 (2000) 34-44
58. Hagel C., Laking G., Laas R., et al. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur J Cancer 32A (1996) 2242-2248
59. DiCioccio R.A., Werness B.A., Peng R., et al. Correlation of TP53 mutations and p53 overexpression in ovarian tumors. Cancer Genet Cytogenet 105 (1998) 93-102
60. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phospatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
61. Peters N., Wellenreuther R., Rollbrocker B., et al. Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 24 (1998) 3-8
62. Steck P.A., Pershouse M.A., Jasser S.A., et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nature Genet 15 (1997) 356-362
63. Newton H.B. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4 (2004) 105-128
64. Liaw D., Marsh D.J., Li J., et al. Germ line mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet 16 (1997) 64-67
65. Lyons C.J., Wilson C.B., and Horton J.C. Association between meningioma and Cowden's disease. Neurology 43 (1993) 1436-1437
66. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
67. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
68. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumor suppressor protein VHL targets hypoxia-inducible factor for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
69. Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation. Exp Nephrol 9 (2001) 235-240
70. Yang H., and Kaelin Jr. W.G. Moleculer pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ 12 (2001) 447-455